Overview

OM336 in Autoimmune Cytopenias

Status:
RECRUITING

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.

Phase:

PHASE1

Details

Lead Sponsor:

Ouro Medicines